Real-World Use of Terlipressin in Cirrhosis and Acute Kidney Injury: Frequent Use Beyond Hepatorenal Syndrome
Clinical Gastroenterology and Hepatology · 2026-04 · 24 (4) · 1079-1091
DOI: 10.1016/j.cgh.2025.08.031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-04. Verfasst von Ann T Ma und 59 weiteren Autor:innen. Beteiligte Einrichtung: Liver Unit, Hospital Clínic of Barcelona, Barcelona, Catalunya, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona, …. Hauptthemen laut MEDLINE: Terlipressin, Acute Kidney Injury, Liver Cirrhosis, Vasoconstrictor Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, Italian Society of Internal Medicine.
Abstract (Originalsprache)
BACKGROUND & AIMS: Terlipressin is indicated to treat hepatorenal syndrome (HRS)-acute kidney injury (AKI) but is likely used outside this primary indication in clinical practice. We aimed to investigate real-world practice patterns on the use of terlipressin in AKI in cirrhosis. METHODS: International prospective study including patients hospitalized for decompensated cirrhosis. This was a subgroup analysis of patients who received terlipressin to treat AKI. Primary outcome was AKI resolution. Secondary outcomes were respiratory failure and 28-day mortality. RESULTS: Among 1456 patients with AKI, 243 (17%) received terlipressin. Terlipressin was predominantly administered as a continuous infusion (75%). The AKI phenotype was HRS-AKI in 50%, acute tubular necrosis (ATN) in 17%, hypovolemic in 25%, and other in 8%. AKI resolution occurred in 49% of the patients, and was lowest in ATN (29%), followed by HRS-AKI (51%) and hypovolemic (63%). ATN was independently associated with lack of AKI resolution (odds ratio, 2.77; 95% confidence interval, 1.24-6.54; P = .02). De novo respiratory failure occurred in 20% of patients. There were no significant differences in the amount of albumin received nor acute-on-chronic liver failure grade between those who did and did not develop respiratory failure. The presence of pneumonia independently predicted respiratory failure (odds ratio, 7.80; 95% confidence interval, 2.43-26.95; P < .001). Mortality rate at 28 days was 36%; ATN and hospital-acquired AKI independently predicted 28-day mortality. CONCLUSIONS: Terlipressin is often used for treatment of AKI outside its primary indication of HRS-AKI. Compared with patients with HRS-AKI, response to terlipressin is significantly lower in patients with ATN, in whom the risks may outweigh the benefits. Respiratory failure is common but does not seem to be driven by the amount of albumin received nor acute-on-chronic liver failure grade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Unit, Hospital Clínic of Barcelona, Barcelona, Catalunya, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona, Catalunya, Spain; Centro de Investigación Biomédica en Red Enfermedade…
- Sherrie and Alan Conover Center for Liver Disease and Transplantation, J.C. Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, Texas.
- Unit of Internal Medicine and Hepatology, Department of Medicine, University and Hospital of Padova, Padova, Italy.
- Department of Hepatology, AIG Hospitals, Hyderabad, India.
- Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Medicine II, LMU University Hospital Munich, Munich, Germany.
Förderung
- NIDDK NIH HHS
- Italian Society of Internal Medicine
Zitieren
APA
Ma, A. T., Juanola, A., Patidar, K. R., Barone, A., Incicco, S., Kulkarni, A. V., Verma, N., Lange, C. M., Xie, Q., Alessandria, C., Cerda Reyes, E., Maiwall, R., Kim, J. H., Marciano, S., Farias, A. Q., Toledo, C., Nardelli, S., Vorobioff, J. D., Roblero, J. P., …, & Montes, P. (2026). Real-World Use of Terlipressin in Cirrhosis and Acute Kidney Injury: Frequent Use Beyond Hepatorenal Syndrome. Clinical Gastroenterology and Hepatology, 24(4), 1079-1091. https://doi.org/10.1016/j.cgh.2025.08.031
Vancouver
Ma AT, Juanola A, Patidar KR, Barone A, Incicco S, Kulkarni AV, et al. Real-World Use of Terlipressin in Cirrhosis and Acute Kidney Injury: Frequent Use Beyond Hepatorenal Syndrome. Clinical Gastroenterology and Hepatology. 2026;24(4):1079-1091. doi:10.1016/j.cgh.2025.08.031
BibTeX
@article{Ma2026,
author = {Ma, Ann T and Juanola, Adrià and Patidar, Kavish R and Barone, Anna and Incicco, Simone and Kulkarni, Anand V and Verma, Nipun and Lange, Christian M and Xie, Qing and Alessandria, Carlo and Cerda Reyes, Eira and Maiwall, Rakhi and Kim, Jeong Han and Marciano, Sebastián and Farias, Alberto Queiroz and Toledo, Claudio and Nardelli, Silvia and Vorobioff, Julio D and Roblero, Juan Pablo and Thévenot, Thierry and Papp, Maria and Maan, Raoel and Solé, Cristina and Cordova-Gallardo, Jacqueline and Simonetto, Douglas A and Fouad, Yasser and Balcar, Lorenz and Raevens, Sarah and Nabilou, Puria and Caraceni, Paolo and Merli, Manuela and Presa, José and Laleman, Wim and Krag, Aleksander and Bruns, Tony and Pereira, Gustavo and Mattos, Angelo Z and Arab, Juan Pablo and Wentworth, Brian and Abdelkader, Nadia Abdelaaty and Wong, Yu Jun and Kim, Sung-Eun and Roux, Olivier and Takkenberg, R Bart and Galante, Antonio and Goncalves, Luciana Lofego and Pyrsopoulos, Nikolaos T and Pérez Hernández, José Luis and Asrani, Sumeet K and Torre, Aldo and Díaz-Ferrer, Javier and Orman, Eric S and Perricone, Giovanni and Gadano, Adrian and Ivashkin, Vladimir and Fassio, Eduardo and Marino, Mónica and Vargas, Victor and Rabinowich, Liane and Montes, Pedro},
title = {Real-World Use of Terlipressin in Cirrhosis and Acute Kidney Injury: Frequent Use Beyond Hepatorenal Syndrome},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {4},
pages = {1079--1091},
doi = {10.1016/j.cgh.2025.08.031}
}
EUVIMED